RxDoctor Payments Data

Stephen Lemons, MD

Family Medicine · Andover, KSNPI 1366403263

Payments from drug & device makers

$11,473in general payments, 2019–2025

Across 768 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$1K
  • AbbVie$1K
  • Lilly USA, LLC$921
  • Novo Nordisk$693
  • Pfizer$635
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$11,453100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca72$1,426
Amgen(2 entities)77$1,169
AbbVie(2 entities)81$1,060
Lilly USA, LLC69$921
Novo Nordisk43$693
Pfizer58$635
Astellas Pharma US Inc32$492
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC29$490
Bayer24$356
Amarin Pharma, Inc.22$306
Merck21$297
Boehringer Ingelheim18$264
Vanda Pharmaceuticals Inc.9$258
GSK17$255
Zyla Life Sciences, Inc.41$222
Johnson & Johnson12$173
Lundbeck LLC10$163
Takeda Pharmaceuticals U.S.A., Inc.10$147
Abbott7$138
Otsuka America Pharmaceutical, Inc.6$136
Sanofi-aventis U.S. LLC7$112
E.r. Squibb & Sons, L.L.C.6$112
Dexcom, Inc.6$109
Novartis8$109
Teva Pharmaceuticals USA, Inc.6$95
Sumitomo Pharma America, Inc.5$86
Ardelyx, Inc.5$84
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$74
Paratek Pharmaceuticals, Inc.3$63
Ironwood Pharmaceuticals, Inc4$62
Menarini Silicon Biosystems, Inc.1$61
Xeris Pharmaceuticals, Inc.4$58
Stryker1$54
Biohaven Pharmaceuticals, Inc.4$53
Almatica Pharma LLC3$52
Mylan Specialty L.p.4$49
Sunovion Pharmaceuticals Inc.3$49
Insulet Corporation3$45
Verona Pharma, Inc.2$44
Eisai Inc.3$42
Axsome Therapeutics, Inc.2$37
Sanofi Pasteur Inc.2$35
Phathom Pharmaceuticals, Inc.2$34
Idorsia Pharmaceuticals US Inc2$31
Genentech USA, Inc.2$29
Esperion Therapeutics, Inc.2$29
IBSA Pharma Inc.2$29
Zimmer Biomet1$24
Nestle Healthcare Nutrition Inc.1$20
Seqirus USA Inc1$20
BD1$20
Exeltis, USA Inc.1$17
Arbor Pharmaceuticals, Inc.1$17
Bausch & Lomb Americas Inc.1$16
Philips North America LLC1$16
Nabriva Therapeutics, PLC1$16
Exact Sciences1$15
Currax Pharmaceuticals LLC1$15
Adlon Therapeutics L.p.1$14
Kowa Pharmaceuticals America, Inc.1$13

How this compares

$11,473 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$398,465
Medicare patients
594
Services billed
50,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$91,079
JanuviaSitagliptin Phosphate90$75,140
JardianceEmpagliflozin93$72,198
Soliqua 100-33Insulin Glargine/Lixisenatide75$72,125
Trelegy ElliptaFluticasone/Umeclidin/Vilanter106$71,858
XareltoRivaroxaban79$65,462
FarxigaDapagliflozin Propanediol83$58,781
MounjaroTirzepatide47$47,423
OzempicSemaglutide38$36,633
Janumet XrSitagliptin Phos/Metformin Hcl32$17,899
Breo ElliptaFluticasone/Vilanterol45$17,863
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$16,979
Tresiba Flextouch U-100Insulin Degludec21$16,877
InvokanaCanagliflozin21$12,948
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr, Janumet$297$103,579136 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$255$98,272165 claims
PfizerEliquis$635$91,079135 claims
Johnson & JohnsonXarelto, Invokana$173$78,410100 claims
Boehringer IngelheimJardiance$264$72,19893 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$112$72,12575 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,426$69,776100 claims
Lilly USA, LLCMounjaro$921$47,42347 claims
Novo NordiskOzempic, Novolog$693$41,53955 claims
Astellas Pharma US IncMyrbetriq$492$8,47611 claims
BayerKerendia$356$7,97512 claims
AbbVieSynthroid$1,060$6,29186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Andover

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →